Gerresheimer (GXI) Investor Update summary
Event summary combining transcript, slides, and related documents.
Investor Update summary
31 Jul, 2025Financial performance and metrics
Net debt to EBITDA ratio was discussed as a key financial metric.
Free cash flow trends were addressed, noting a recent negative movement but expectations for stabilization.
Business operations and partnerships
Drug delivery systems, supply ID, and segment plastics and devices were highlighted as operational areas.
Primary packaging glass was mentioned as a complex area within the business.
Collaboration with a private equity firm was referenced.
Corporate governance and investor relations
Corporate governance and investor feedback were noted as areas of focus.
Eminence Capital was identified as a significant holding partner.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Gerresheimer
- Q2 2024 showed resilient results, strong Plastics & Devices, and a major pharma acquisition.GXI
Q2 20243 Feb 2026 - 2024 guidance cut as vial demand lags and US plant flooding impacts results.GXI
Q3 2024 TU20 Jan 2026 - Strong Q4 growth and Bormioli integration drive robust 2025 outlook and margin expansion.GXI
Q4 202410 Dec 2025 - Sustainable growth fueled by innovation, digitalization, and global capacity expansion.GXI
Investor Presentation7 Dec 2025 - Revenue up 11.6% on Bormioli Pharma deal, but net income negative amid higher debt.GXI
Q1 202529 Nov 2025 - 2025 outlook and dividend cut as weak H1 demand prompts lower growth and margin guidance.GXI
Q2 2025 TU24 Nov 2025 - Revenue up 19.6% with Bormioli Pharma, but margins and 2025 outlook were revised downward.GXI
Q2 202516 Nov 2025 - Organic revenue and EBITDA fell, guidance was cut, and transformation actions were launched.GXI
Q3 202522 Oct 2025 - Guidance cut after weak Q3 and 9M, with organic revenue and EBITDA both down year-over-year.GXI
Q3 2025 TU10 Oct 2025